MX2016014695A - Combinaciones de bromuro de tiotropio, formoterol y budesonida para el tratamiento de enfermedad pulmonar obstructiva cronica. - Google Patents

Combinaciones de bromuro de tiotropio, formoterol y budesonida para el tratamiento de enfermedad pulmonar obstructiva cronica.

Info

Publication number
MX2016014695A
MX2016014695A MX2016014695A MX2016014695A MX2016014695A MX 2016014695 A MX2016014695 A MX 2016014695A MX 2016014695 A MX2016014695 A MX 2016014695A MX 2016014695 A MX2016014695 A MX 2016014695A MX 2016014695 A MX2016014695 A MX 2016014695A
Authority
MX
Mexico
Prior art keywords
copd
treatment
formoterol
budesonide
combinations
Prior art date
Application number
MX2016014695A
Other languages
English (en)
Inventor
Ullmann Michiel
Original Assignee
Teva Pharmaceuticals Europe B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51032625&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016014695(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceuticals Europe B V filed Critical Teva Pharmaceuticals Europe B V
Publication of MX2016014695A publication Critical patent/MX2016014695A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Esta invención provee un producto de combinación que comprende una composición de antagonista muscarínico de acción prolongada inhalable (LAMA) para usarse en el tratamiento a largo plazo de EPOC combinada con una composición de dosis fija inhalable que comprende budesonida y formoterol o una sal farmacéuticamente aceptable del mismo para administración pro re nata (p.r.n.) como una medicamento de rescate para el tratamiento de las exacerbaciones agudas de EPOC.
MX2016014695A 2014-05-12 2015-05-08 Combinaciones de bromuro de tiotropio, formoterol y budesonida para el tratamiento de enfermedad pulmonar obstructiva cronica. MX2016014695A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1408387.7A GB201408387D0 (en) 2014-05-12 2014-05-12 Treatment of respiratory disorders
PCT/EP2015/060256 WO2015173153A1 (en) 2014-05-12 2015-05-08 Combinations of tiotropium bromide, formoterol and budesonide for the treatment of copd

Publications (1)

Publication Number Publication Date
MX2016014695A true MX2016014695A (es) 2017-05-04

Family

ID=51032625

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016014696A MX2016014696A (es) 2014-05-12 2015-05-08 Combinaciones de formoterol y budesonida para el tratamiento de enfermedad pulmonar obstructiva cronica.
MX2016014695A MX2016014695A (es) 2014-05-12 2015-05-08 Combinaciones de bromuro de tiotropio, formoterol y budesonida para el tratamiento de enfermedad pulmonar obstructiva cronica.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016014696A MX2016014696A (es) 2014-05-12 2015-05-08 Combinaciones de formoterol y budesonida para el tratamiento de enfermedad pulmonar obstructiva cronica.

Country Status (17)

Country Link
US (2) US20170202858A1 (es)
EP (2) EP3142653A1 (es)
JP (4) JP2017515835A (es)
KR (2) KR20170003601A (es)
CN (2) CN106488770A (es)
AR (2) AR100369A1 (es)
AU (2) AU2015261104A1 (es)
BR (2) BR112016026369A2 (es)
CA (2) CA2948574A1 (es)
CL (1) CL2016002848A1 (es)
EA (2) EA201692278A1 (es)
GB (1) GB201408387D0 (es)
IL (2) IL248875A0 (es)
MX (2) MX2016014696A (es)
PE (1) PE20170073A1 (es)
UA (2) UA119773C2 (es)
WO (2) WO2015173153A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104758294A (zh) * 2014-12-17 2015-07-08 广州呼吸疾病研究所 用于copd、哮喘治疗的吸入药物组合物及其制备方法
WO2017108917A1 (en) * 2015-12-22 2017-06-29 Astrazeneca Ab Pharmaceutical compositions for use in the treatment of chronic obstructive pulmonary disease
CN106466322A (zh) * 2016-08-25 2017-03-01 杭州百诚医药科技股份有限公司 一种以布***和噻托溴铵为活性成分的复方制剂
WO2018071435A1 (en) * 2016-10-11 2018-04-19 Microdose Therapeutx, Inc. Inhaler and methods of use thereof
WO2019142214A1 (en) 2018-01-19 2019-07-25 Cipla Limited Pharmaceutical composition comprising tiotropium for inhalation
CA3091804A1 (en) * 2018-02-23 2019-08-29 Microdose Therapeutx, Inc. Inhaler and methods of use thereof
CN116077471A (zh) * 2021-11-08 2023-05-09 上海臣邦医药科技股份有限公司 一种供吸入用的粉雾剂组合物及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1086697A2 (en) * 1991-12-18 2001-03-28 AstraZeneca AB New combination of formoterol and budesonide
SK282826B6 (sk) * 1991-12-18 2002-12-03 Aktiebolaget Astra Farmaceutická kompozícia na podávanie inhaláciou s obsahom formoterolu a budesonidu a jej použitie
SE9703407D0 (sv) * 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) * 1998-06-11 1998-06-11 Astra Ab New use
DE10130371A1 (de) * 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
UA80123C2 (en) * 2002-04-09 2007-08-27 Boehringer Ingelheim Pharma Inhalation kit comprising inhalable powder of tiotropium
SE526509C2 (sv) * 2003-06-19 2005-09-27 Microdrug Ag Kombinerade doser av formoterol och budesonid separerade på en gemensam dosbädd
US20070293460A1 (en) * 2005-10-31 2007-12-20 Richie's Pharmacy And Medical Supply, Incorporated Delivery of a combination therapy for asthma and chronic obstructive pulmonary disease
US20090291146A1 (en) * 2006-08-09 2009-11-26 Glaxo Group Limited Process for manufacturing lactose
KR20090121338A (ko) * 2007-02-19 2009-11-25 씨아이피엘에이 엘티디. 두 개 이상의 기관지확장제 또는 기관지확장제와 코르티코스테로이드의 약제학적 조합
JP2010539182A (ja) * 2007-09-12 2010-12-16 グラクソ グループ リミテッド 治療剤の新規組み合わせ
TR201000680A2 (tr) * 2010-01-29 2011-08-22 B�Lg�� Mahmut Tiotropyum, formoterol ve budesonid içeren farmasötik bileşimler
WO2011131663A1 (en) * 2010-04-21 2011-10-27 Chiesi Farmaceutici S.P.A. "process for providing particles with reduced electrostatic charges"
BR112013001119A2 (pt) * 2010-07-16 2016-05-24 Cipla Ltd composição farmacêutica, processo para fabricar uma composição farmacêutica, uso de r(+)budesonida e um broncodilatador, e método de profilaxia ou tratamento de uma doença respiratória, inflamatória ou obstrutiva das vias aéreas
JOP20120023B1 (ar) * 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
RU2460547C1 (ru) * 2011-04-08 2012-09-10 Валерий Феофанович Ушаков Способ пролонгированной профилактики холодового бронхоспазма у больных с "микст-патологией"
WO2014007770A2 (en) * 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising corticosteroid and sorbitol
ITMI20130571A1 (it) * 2013-04-10 2014-10-11 Zambon Spa Composizione farmaceutica contenente budesonide e formoterolo

Also Published As

Publication number Publication date
CA2948574A1 (en) 2015-11-19
CL2016002848A1 (es) 2017-07-07
AR100368A1 (es) 2016-09-28
EP3142654A1 (en) 2017-03-22
CN106470700A (zh) 2017-03-01
JP2017515835A (ja) 2017-06-15
BR112016026369A2 (pt) 2018-05-15
EP3142653A1 (en) 2017-03-22
CA2948553A1 (en) 2015-11-19
WO2015173154A9 (en) 2016-03-03
MX2016014696A (es) 2017-05-04
KR20170003601A (ko) 2017-01-09
GB201408387D0 (en) 2014-06-25
US20170209464A1 (en) 2017-07-27
US20170202858A1 (en) 2017-07-20
UA119773C2 (uk) 2019-08-12
AR100369A1 (es) 2016-09-28
IL248874A0 (en) 2017-01-31
JP2020023536A (ja) 2020-02-13
EA201692278A1 (ru) 2017-02-28
JP2017515833A (ja) 2017-06-15
KR20170003600A (ko) 2017-01-09
PE20170073A1 (es) 2017-03-24
CN106488770A (zh) 2017-03-08
JP2020023537A (ja) 2020-02-13
WO2015173153A1 (en) 2015-11-19
AU2015261104A1 (en) 2016-11-17
BR112016026371A2 (pt) 2018-06-19
AU2015261103A1 (en) 2016-11-17
EA201692276A1 (ru) 2017-03-31
IL248875A0 (en) 2017-01-31
WO2015173154A1 (en) 2015-11-19
UA119774C2 (uk) 2019-08-12

Similar Documents

Publication Publication Date Title
MX2016014695A (es) Combinaciones de bromuro de tiotropio, formoterol y budesonida para el tratamiento de enfermedad pulmonar obstructiva cronica.
MY187047A (en) Selective pyy compounds and uses thereof
FI3674298T3 (fi) Substituoituja indatsoleja, menetelmä niiden valmistamiseksi, niitä sisältäviä farmaseuttisia valmisteita sekä niiden käyttö lääkkeiden valmistukseen
GB2538682A (en) Nasal drug products and methods of their use
JO3784B1 (ar) الاستخدام المشترك للاجسمام المضادة pd-1 ومضادات m-csf في علاج السرطان
EP3515420C0 (en) PHARMACEUTICAL COMPOSITIONS FOR USE IN BLEPHARITIS THERAPY
WO2014064410A8 (en) Pharmaceutical composition
TR201000680A2 (tr) Tiotropyum, formoterol ve budesonid içeren farmasötik bileşimler
EP3526195A4 (en) SULFOXYALKYL ORGANONITRO AND RELATED COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR USE IN MEDICINE
MD20170048A2 (ro) Formulare pe bază de acetat de abirateronă şi procedee de utilizare a acesteia
PH12015501398A1 (en) New cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activity
MX2015012650A (es) Metodos para el tratamiento de angioedema mediado receptores debradicinina b2.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
NZ716765A (en) Pharmaceutical combinations for the treatment of cancer
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2015009891A (es) Composiciones farmaceuticas que comprenden particulas cristalinas de multicomponentes adecuadas para usar en terapia de inhalacion.
MX2017014776A (es) Combinacion farmaceutica de everolimus con dactolisib.
WO2016020408A3 (en) Compounds for preventing ototoxicity
WO2014122460A3 (en) Pemetrexed complexes and pharmaceutical compositions containing pemetrexed complexes
MX2017008497A (es) Nuevos compuestos heterocíclicos y su uso tanto en medicina como en cosmética.
EP3222271A4 (en) Stable pharmaceutical composition comprising pemetrexed or pharmaceutically acceptable salt thereof
IN2013MU03838A (es)